Adam D. Levy - 01 Apr 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Financial Officer
Signature
/s/ Adam D. Levy
Issuer symbol
ACRV
Transactions as of
01 Apr 2025
Net transactions value
$0
Form type
4
Filing time
03 Apr 2025, 16:30:52 UTC
Next filing
05 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Stock Option (Right to Buy) Award $0 +35,209 $0.000000 35,209 01 Apr 2025 Common Stock 35,209 $1.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the shares subject to the option vest on April 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.